Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756Phase 3Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of setmelanotide in acquired hypothalamic obesity (HO), sponsored by Rhythm Pharmaceuticals. Started Apr 2023; status: active, not recruiting.
02
Drugs
setmelanotide
03
Conditions
acquired hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT05774756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774756.